Background: This phase II study investigated the efficacy and safety of everolimus, an inhibitor of mammalian target of rapamycin (mTOR), in locally advanced or metastatic thyroid cancer.
introduction
Thyroid cancer is a rare malignancy that is increasing in its incidence [1] . It is a heterogeneous disease, with varying histology and differentiation. For differentiated thyroid cancer, the current standard of care is primary surgery and thyroid stimulation hormone suppression with supraphysiologic thyroid hormone administration. Ablation of the thyroid remnant with radioactive iodine (RAI) 131 is added. These treatments showed an overall survival (OS) rate of 90% at 20 years. However, the prognosis of RAI-refractory or recurrent or metastatic disease is dismal and traditional cytotoxic chemotherapy, such as doxorubicin, has shown to have minimal efficacy [2] . Medullary thyroid cancer (MTC) accounts for ∼4% of all thyroid cancers [3] . Although the 10-year survival rate for MTC patients is 80%, 10-year survival rates drops down to 31% when distant metastases are present. Anaplastic thyroid cancer (ATC) accounts for 1.6% of all thyroid cancers, but is known to be the most lethal of all thyroid cancers, with the median life expectancy about 4 months [4] . Therefore, successful treatment of advanced thyroid cancer of all histologic types is a challenge.
Several targeted agents have been developed in thyroid cancer and the majority of recent experimental drugs focus on the inhibition of angiogenic factors, such as vascular endothelial growth factor (VEGF) receptor, which play a critical role in thyroid cancer cell growth and metastasis [5] [6] [7] [8] [9] . Most trials were enriched in differentiated thyroid cancer and MTC while little is known about ATC. In addition, the efficacy of many targeted agents was limited to disease stabilization, with modest objective response. Therefore, new drugs are promptly needed to treat RAI-refractory or advanced thyroid cancer.
Phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a potentially important and effective therapeutic target in thyroid cancer [10, 11] . Many genetic alterations in the PI3K/Akt pathway were revealed in thyroid cancer, including PIK3CA amplification and mutations, Ras mutations, and PTEN mutations [12] . Mammalian target of rapamycin (mTOR) signaling was shown to be activated in aggressive PTC in which mTOR inhibitor was shown to induce antitumor effects both in vivo and in vitro [13] . Recently, inhibition of mTOR pathway induced a significant dose-dependent growth inhibition in MTC and ATC cells [14, 15] . These data implicate that mTOR signaling is a common element in all histologies of thyroid cancers.
Everolimus is an orally bioavailable inhibitor of the mTOR pathway. The effects of everolimus in cancer cells include reduced growth and proliferation as well as inhibition of protein translation and VEGF production [16] . It has undergone extensive clinical trials for its utility, alone and in combination, as an anticancer agent with the best results seen in patients with renal cell carcinoma.
The aim of this phase II study was to investigate the efficacy and tolerability of everolimus in the treatment of all histological types of locally advanced or metastatic thyroid cancer. 
response evaluation
Patients were followed by computed tomography or magnetic resonance imaging scans of the neck, chest, and abdomen that were carried out every 8 weeks and when disease progression was suspected. Based on the Response Evaluation Criteria in Solid Tumor (RECIST version 1.1) criteria, responses were assessed and categorized as CR, PR, SD, and PD [17] .
safety and tolerability
Throughout the study, safety was assessed by monitoring and recording of adverse events (AEs), vital signs, clinical chemistry, hematology, and urinalysis. Event severity was graded according to the National Cancer Institute Common Terminology Criteria Adverse Events version 3.0. Treatment interruption and dose reductions to lower doses of everolimus (5 and 2.5 mg) were required for grades 3 and 4 toxicities per a study protocol algorithm.
statistical analysis
For sample size calculation, the study used a single-stage design based on exact binomial distribution. A study requires 36 subjects to decide whether the rate of disease control at 12 weeks is ≤0.20 or ≥0.40 with type I error level of 0.10 and type II error of 0.10. Total number of patients will be 40 considering follow-up loss rate 10%.
Actuarial survival curves were estimated using the Kaplan-Meier method, and 95% CIs for the medians were provided for PFS and OS. Correlation of different variables was analyzed using the nonparametric Spearman rank test. All statistical analyses were carried out with SPSS 16.0 (SPSS, Chicago, IL, USA).
results

patient characteristics
Between June 2010 and August 2011, a total of 40 patients were enrolled. Seventeen patients were continuing treatment at the time of data cut off (18 March 2012) . One patient discontinued everolimus because of adverse events, 14 had disease progression, 5 withdrew consent (2 had withdrawn consent before the start of study drug and 3 withdrew consent during the treatment). The demographics and baseline characteristics of study participants are listed in Table 1 . The median age of patients was 61 years (range 36-83 years), and there were 14 (35%) males and 26 (65%) females. The most common type of thyroid cancer was papillary (40%), then medullary, follicular, anaplastic, and poorly differentiated, in the order of frequency. At study entry, 1 (2%) patient had locoregionally advanced disease and 39 (98%) had distant metastases. Almost all patients (36 of 40, 90%) had received previous treatment before study entry; the most common previous treatments were surgery (68%), 131 I (60%), chemotherapy (22%), radiotherapy (15%), and tyrosine kinase inhibitor (2%). Four (10%) patients were treatment-naïve.
original articles Annals of Oncology efficacy Thirty-eight patients were assessable for objective tumor response ( Table 2 ). The primary end point which was the DCR (PR + SD ≥ 12 weeks) was observed in 31 (81%) patients. A confirmed objective PR was achieved in 2 (5%) patients and SD was reported in 29 (76%) patients. Seventeen (45%) patients showed durable SD (SD ≥ 24 weeks) and clinical benefit (PR + durable SD) was reported in 19 (50%) patients. Seven (18%) patients showed PD as best response. For the two patients with confirmed objective response, time to response was 31 and 16 weeks, and duration of response was 21+ and 24+ weeks, respectively. As shown in a waterfall plot (Figure 1 ), 24 patients (63%) experienced tumor shrinkage (range −35% to −9%) during everolimus treatment. Notably, one patient with ATC showed a marked reduction of tumor. Her tumor shrinkage in the right neck node was −21% after 4 weeks of treatment (supplementary Figure S1 , available at Annals of Oncology online). There was no apparent association between efficacy and histology, but it is noteworthy to see a high proportion of DCR in differentiated thyroid cancer and MTC patients (supplementary Table S1 , available at Annals of Oncology online).
With a median follow-up duration of 11 months (range 1-24 months), the median PFS of all patients was 47 weeks (95% CI 14.9-78.5) and 16 (40%) patients had no progression at the time of analysis (Figure 2 ). The PFS according to histology was 43 weeks in differentiated thyroid cancer, not reached in MTC, and 10 weeks in ATC and 46 weeks in poorly differentiated thyroid cancer, respectively. Thirty-two patients (80%) are still alive, and the median OS has not yet been reached (supplementary Figure S2 , available at Annals of Oncology online).
safety and tolerability
The median duration of everolimus therapy was 6.7 months (range 0.7-21.1 months). AEs were predominantly grade 1 or 2, and the most common events included mucositis (84%), anorexia (44%), and aspartate transaminase (AST)/alanine transaminase (ALT) elevation (26%) ( Table 3 ). The most common grade 3 AEs were mucositis (15%) and diarrhea (10%). One patient (2%) discontinued treatment because of treatmentrelated toxicity. She suffered from everolimus-related interstitial pneumonitis G4 which required broad-spectrum IV antibiotics and corticosteroid. She recovered from pneumonitis 2 weeks after hospitalization. One patient (2%) suffered from infection G5 resulting from acute pyelonephritis which was not considered by the investigator to be related.
tumor markers
Serum calcitonin and CEA levels were measured for nine MTC patients and thyroglobulin level was measured for 14 PTC patients. With regard to biochemical response, calcitonin and CEA concentrations were ≥50% lower than baseline, defined as PR, in three (30%) and four (44%) of patients, respectively. Two (22%) patients showed PD in calcitonin response, while one (11%) showed PD in CEA response. For thyroglobulin levels, five (35%) patients showed PR, and remaining patients showed SD as best response. A correlation was observed between a decrease in the thyroglobulin concentration with the reduction 
FDG-PET response and immunohistochemistry
Among 40 patients, 20 (50%) had assessable 18 F -FDG-PET studies at baseline and after one cycle of therapy. At baseline, the median number of index lesions per patient identified was two lesions (range 1-5), and the mean SUV max was 13.1. Comparison of FDG avidity, quantified by SUV, a significantly higher FDG uptake was found in ATC compared with DTC and original articles Annals of Oncology MTC (P = 0.044). The mean SUV max decreased from 13.1 to 8.5 after one cycle of everolimus (P = 0.0005). The reduction of mean SUV max was statistically significant in ATC, MTC, and PTC, but not in FTC. A correlation was noted between the PET response and PFS (r = 0.560, P = 0.010). Three ATC patients and one MTC patient had available tumor tissue sampled immediately before the start of everolimus treatment. Immunohistochemistry of glucose transporter 1 (GLUT1) and hexokinase (HK) II were carried out. Increased GLUT1 and HKII expression were seen in all three ATC patients contrary to a MTC patient. It is notable that these patients also showed high baseline glucose uptake in tumor, represented by SUV max (supplementary Figure S4 and Table S2 , available at Annals of Oncology online).
western blot
We obtained both pre-and post-treatment biopsy samples from one ATC patient. After one cycle of treatment, his follow-up neck CT scan showed progression of right neck mass, and he also had newly developed metastasis to brain and lung. The immunohistochemical staining of GLUT1 and HKII in pretreatment biopsy sample showed strong and partly positive staining, respectively. The western blot before and after treatment showed the reduction in phosphorylation of mTOR, S6K, and Akt at Ser473, but a dramatic increase in phosphorylation of ERK was seen (supplementary Figure S5 , available at Annals of Oncology online).
discussion
This phase II trial evaluated a single-agent everolimus in locally advanced or metastatic thyroid cancer patients. A confirmed objective response was observed in only two patients (5%). Disease control was observed in 31 (81%) patients and the median PFS was 47 weeks in all patients. Everolimus was well tolerated in our study with manageable toxicity. In general, the AEs observed were mild to moderate and were similar to previously reported toxicities [18, 19] . The most common treatment-related AEs were mucositis, anorexia, and AST/ALT elevation. Most of the observed AEs were managed effectively with dose reduction and symptomatic therapy.
Consistent with the previous report, changes in thyroglobulin concentration was correlated with the tumor response. While all MTC patients showed SD, the percent change in calcitonin and CEA concentrations from baseline reflected the duration of SD. Our data suggest that the changes in tumor markers during everolimus treatment reflect changes in tumor burden and can be used as useful pharmacodynamic markers.
Our western data unravel pharmacodynamics of target inhibition and rapid development of adaptive resistance of cancer cells by activating alternative signaling pathway. An important implication of our findings is that there is a feedback loop between mTOR pathway and RAS/MAPK/ERK signaling. Carracedo et al. [20] showed that mTORC1 inhibition can activate MAPK through a PI3K-dependent feedback loop in human cancer. Activation of different prosurvival signaling pathway upon mTOR inhibition implicates that the activated pathway is capable of tumor progression and that a single molecular targeted agent may not be sufficient to control the heterogeneous signaling of tumor population. This mechanism of early adaptive resistance explains as to why the tumor shows an initial response followed by rapid progression. This highlights the need to pursue the potential therapeutic benefit of combinatorial therapy with MEK and mTOR inhibitors to enhance antitumoral activity.
Unexpectedly, we observed a dramatic tumor reduction in an ATC patient. With pretreatment biopsy and whole blood sample from the patient, we are currently exploring the mutational landscape using whole exome sequencing. Future investigations should focus on genomic analysis of responders to explore the 'Achilles heel' of this lethal disease.
In conclusion, everolimus had a limited activity in locally advanced or metastatic thyroid cancer patients, but the clinical benefit is noteworthy. The efficacy of everolimus needs to be confirmed in a large trial in future studies. 
